// App-Quantinova.ai

10503 : Circulating tumor cell counts (CTC) as prognostic of overall survival (OS) in SWOG S0421-docetaxel with or without atrasentan for metastatic castration resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Nicholas J. Vogelzang

Principal Investigators

  • Louis M. Fink

  • Mark Garzotto

  • Philip C. Mack

  • Primo Lara

  • Celestia S. Higano

  • Maha Hussain

  • David I. Quinn

  • Richard J Cote

  • Ian Murchie Thompson

  • Amir Goldkorn

  • Catherine M. Tangen

  • Przemyslaw Twardowski

  • Peter J. Van Veldhuizen

  • Neeraj Agarwal

  • Michael Anthony Carducci

  • J. P. Monk

  • Ram H Datar

Medical Centers

  • Nevada Cancer Institute, Las Vegas, NV

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • SWOG Statistical Center, Seattle, WA

  • City of Hope, Duarte, CA

  • University of California, San Francisco, CA

  • University of Miami Miller School of Medicine, Miami, FL

  • Comprehensive Cancer Centers of Nevada, The US Oncology Network, Las Vegas, NV

  • Portland Veterans Affairs Medical Center, Portland, OR

  • University of Texas Health Science Center San Antonio, San Antonio, TX

  • Johns Hopkins University, Baltimore/ECOG, Baltimore, MD

  • University of Kansas Medical Center, Westwood, KS

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • atrasentan

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved